Weight-loss medications
Retatrutide produced 28.7% weight loss in trials vs Wegovy 7.2 mg's 20.7%. Retatrutide isn't UK-approved yet; Wegovy is the current option.
Weight-loss medications
Retatrutide's main side effects in trials: nausea (43%), heart rate increase of ~6.7 bpm, and dysesthesia (20.9%) at the 12 mg dose. Not yet UK-approved.
Weight-loss medications
In trials, retatrutide reached 28.7% weight loss vs Mounjaro's 22.5%. Retatrutide isn't UK-approved yet, so Mounjaro is the current option.
Weight-loss medications
Mounjaro produced more weight loss than CagriSema in REDEFINE 4: 25.5% vs 23.0% over 84 weeks. Only Mounjaro is licensed and available in the UK.
Weight-loss medications
CagriSema: 22.7% weight loss in REDEFINE 1, the highest for any Novo Nordisk obesity drug. Lost head-to-head to Mounjaro. Not yet UK-approved.
Weight-loss medications
CagriSema isn't yet available in the UK. No MHRA filing as of May 2026. Private launch likely 2026-2027, NHS access from 2028.
Wegovy compatibility
You can take Wegovy with rheumatoid arthritis. Find out how it interacts with RA medications and why weight loss may improve disease activity.
Wegovy compatibility
You can take Wegovy with chronic kidney disease. Find out which stages are safe, how to monitor, and why it may protect kidney function.
Wegovy compatibility
You can take Wegovy after a gastric band, but the combination needs medical supervision. Find out what to expect from your bariatric team and GP.
Wegovy compatibility
Wegovy is safe to take with fibromyalgia. What the evidence shows on weight loss, pain, and fatigue, plus practical guidance for managing both.
As seen on
As seen on